Doctor and patient

What we do

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.

Sareum's most advanced development programme (Chk1) was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.

Pipeline_diagram.png

Further Information

Find out more about our drug development programs

  • @Sareumplc Latest tweet

    Immuno-oncology (including Sareum's SDC-1802): All you wanted to know but were too afraid to ask… https://t.co/rM9L5tvHvs via @Sareumplc
    View more